On Thursday morning, Rockwell Medical (NASDAQ:RMTI) announced positive top-line results from CRUISE-1, the first of two Phase 3 trials for SFP, which is simply a salt form of iron that can be added to dialysate to maintain chronic kidney disease (CKD) patients' hemoglobin. Iron deficiency anemia is an ongoing concern for dialysis patients, and SFP has the potential to become the market leader in iron replacement. Not long ago, I wrote an article arguing that due to pending catalysts and the advancement of their business model, the short thesis for Rockwell Medical had played out. The successful release of CRUISE-1 data confirms one of the planks of my argument, and these positive results bode well for CRUISE...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|